Latest Regulatory Approval News

Mineral Commodities Ltd reported a steep net loss of USD 65.1 million for H1 2024, driven by operational disruptions at its Tormin mine and strategic moves including the sale of its Skaland Graphite Project.

Pioneer Lithium Ltd has strategically acquired two uranium projects in Colorado and Namibia, marking a significant diversification into critical energy minerals. The company plans a A$1.675 million equity raise to fund exploration and development of these promising assets.

Element 25 Limited reports a transformative quarter with a 142% resource increase at Butcherbird, a compelling $561 million NPV feasibility study, and a $268 million US Department of Energy grant to advance its Louisiana battery-grade manganese refinery.

Nickel Industries delivered a record US$72.4 million EBITDA in Q4 2024, driven by strong operational milestones and strategic project advancements. However, currency fluctuations posed a significant challenge, underscoring the company’s exposure to foreign exchange risks.

MRG Metals reports significant progress in its Mozambique Heavy Mineral Sands joint venture with Sinowin Lithium, alongside promising rare earth element exploration results in Zimbabwe, positioning the company for potential growth in strategic mineral markets.

A1 Investments & Resources Ltd reported a modest cash outflow for Q1 2024 while actively pursuing renewable energy acquisitions in Japan and Australia, contingent on regulatory approvals and shareholder consent.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

Tivan Limited has advanced its Speewah Fluorite Project with a $7.4 million government grant and Major Project Status, alongside a joint venture MoU with Sumitomo Corporation and promising drilling results at Sandover.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.

Lanthanein Resources has completed initial drilling phases at its Lady Grey Project and secured a six-month extension on its farm-in agreement, positioning the company for a critical assessment of its gold exploration prospects.